News|Articles|September 17, 2026

SOHO 2026: Novel Frontline Strategies and Molecular Approaches in Lymphoma

Fact checked by: Roman Fabbricatore, Russ Conroy

SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.

The 2026 Society of Hematologic Oncology (SOHO) Annual Meeting featured several sessions focused on aggressive B-cell lymphoma (ABCL), including presentations exploring augmented frontline regimens, emerging genomic classifiers, and novel strategies for a patient population historically underserved by intensive chemoimmunotherapy. Together, these sessions contextualized where the treatment paradigm for diffuse large B-cell lymphoma (DLBCL) currently stands and where it is headed.

Related to this article

Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.

November 7th, 2026

Building Systems to Catch Liver and Other Cancers in Patients With MASLD

Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.

At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.

November 7th, 2026

Eliciting Patient Preferences to Guide HCC Treatment Decisions

At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.

Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.

November 6th, 2026

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.

Human liver anatomy structure, liver disease. 3d illustration | Image Credit: © Crystal light - stock.adobe.com

November 6th, 2026

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.

Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.

November 6th, 2026

How Should Liver Function and Patient Values Guide HCC Treatment?

Andrew Moon, MD, MPH, explained how liver function, biomarkers, and patient preferences should shape multidisciplinary treatment decisions in HCC.

Human liver anatomy structure, 3d illustration | Image Credit: © Crystal light - stock.adobe.com

November 6th, 2026

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Hashem B. El-Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine screening.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

November 6th, 2026

Training, Invasiveness, and Workload Behind Falling Prostate Brachytherapy Use

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.